Together, our results indicate that BLT2 has a potential role in KRAS-driven lung cancer (the proposed signaling model is summarized in Fig. 6b) and that inhibition of the BLT2 cascade may be a new therapeutic strategy against KRAS-driven lung cancer. Here, KRAS is linked to lung carcinoma.